Yahoo
    NasdaqGS - Nasdaq Real Time Price USD

    Savara Inc. (SVRA)

    4.8200 -0.1300 (-2.63%)
    At close: 4:00:00 PM EDT
    4.8686 +0.0486 (+1.01%)
    After hours: 7:20:59 PM EDT
    Trade Savara on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for SVRA
    • Previous Close 4.9500
    • Open 4.9361
    • Bid 3.5000 x 200
    • Ask 6.1500 x 200
    • Day's Range 4.7498 - 4.9700
    • 52 Week Range 3.8600 - 7.0050
    • Volume 1,409,437
    • Avg. Volume 1,986,112
    • Market Cap (intraday) 990.317M
    • Beta (5Y Monthly) 0.20
    • PE Ratio (TTM) --
    • EPS (TTM) -0.5800
    • Earnings Date (est.) Nov 11, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 11.06
    • Zacks Rating Neutral

    Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

    www.savarapharma.com

    70

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Savara Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    SVRA
    20.07%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    SVRA
    12.09%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    SVRA
    31.34%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    SVRA
    315.52%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings -40.23M
    Profit Margin 0.00%

    Q2

    FY25

    Q3

    FY25

    Q4

    FY25

    Q2

    FY26

    -40M
    -30M
    -20M
    -10M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    9.00
    11.06 Average
    4.8200 Current
    16.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 10/7/2026
    Analyst JP Morgan
    Rating Action Initiated
    Rating Overweight
    Price Action Announces
    Price Target 12
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -50.15%

    • Return on Equity (ttm)

      -105.48%

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -139.31M

    • Diluted EPS (ttm)

      -0.5800

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      174.82M

    • Total Debt/Equity (mrq)

      21.17%

    • Levered Free Cash Flow (ttm)

      -57.19M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    AQST Aquestive Therapeutics, Inc.
    3.8900 -3.71%
    SLDB Solid Biosciences Inc.
    6.20 -2.97%
    SYBX Synlogic, Inc.
    0.9600 -8.57%
    XERS Xeris Biopharma Holdings, Inc.
    10.71 -0.37%
    OVID Ovid Therapeutics Inc.
    2.5400 -0.78%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: